-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $89

Benzinga·10/20/2026 11:24:46
Listen to the news
BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $75 to $89.